In an era of personalized medicine with tailored treatment expectations, we need smaller trials in homogeneous populations with highevent rates. Conclusive results from such trials can be used to help individualize treatments for patients with asthma according to phenotype and age.
In moderate-to-severe asthma, as-needed albuterol-budesonide reduced severe exacerbations vs. albuterol alone
Marco Confalonieri
2022-01-01
Abstract
In an era of personalized medicine with tailored treatment expectations, we need smaller trials in homogeneous populations with highevent rates. Conclusive results from such trials can be used to help individualize treatments for patients with asthma according to phenotype and age.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Annals Journal Club.pdf
Accesso chiuso
Descrizione: Articolo
Tipologia:
Documento in Versione Editoriale
Licenza:
Digital Rights Management non definito
Dimensione
974.42 kB
Formato
Adobe PDF
|
974.42 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
